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Many poxviruses express a 35–40-kDa secreted protein, termed “ T1” (for leporipoxviruses) or “35kDa” (for orthopoxvi-
ruses), that binds CC-chemokines with high affinity but is unrelated to any known cellular proteins. Many previously identified
poxvirus cytokine-binding proteins display strict species ligand-binding specificity. Because the T1 and 35kDa proteins share
only 40% amino acid identity, we compared the abilities of purified myxoma virus-T1 (M-T1) and vaccinia virus (strain Lister)-
and rabbitpox virus-35kDa proteins to inhibit human CC-chemokines in vitro. All three proteins were equally effective in
preventing several human CC-chemokines from binding to target chemokine receptors and blocking subsequent intracellular
calcium release. The inhibitory affinities were comparable (Ki 5 0.07–1.02 nM). These proteins also displayed similar abilities
to inhibit (IC50 5 6.3–10.5 nM) human macrophage inflammatory protein-1a-mediated chemotaxis of human monocytes.
None of the viral proteins blocked interleukin-8-mediated calcium flux or chemotaxis of human neutrophils, confirming that
the biological specificity of the T1/35kDa family is targeted inhibition of CC-chemokines. Despite the significant sequence
divergence between the leporipoxvirus T1 and orthopoxvirus 35kDa proteins, our data suggest that their CC-chemokine
binding and inhibitory properties appear to be species nonspecific and that the critical motifs most likely reside within the
limited regions of conservation. © 1998 Academic Press
INTRODUCTION
Poxviruses are large double-stranded DNA viruses that
encode an impressive array of gene products dedicated to
subverting the innate and acquired immune responses of
their host animals (Kotwal, 1997; McFadden, 1995; Smith et
al., 1997b; Spriggs, 1996). Such mechanisms for immune
modulation directed by poxviruses include disruption of the
host complement cascade (Isaacs and Moss, 1995), inhibi-
tion of apoptosis (Barry and McFadden, 1998; Turner and
Moyer, 1998), downmodulation of immunoregulatory cell-
surface molecules (Barry et al., 1995; Boshkov et al., 1992;
McFadden and Kane, 1994), and interference with a variety
of diverse immune regulators (McFadden et al., 1995, 1998;
Spriggs, 1996). In particular, some of the secreted poxvirus-
encoded glycoproteins possess sequence similarities to
cytokine receptors and function by binding and neutralizing
the activities of antiviral cytokines before engagement with
their cognate cellular receptors. To date, poxviral cytokine
receptor mimics, or “viroceptors,” have been identified for
receptors of tumor necrosis factors (TNFs) (Loparev et al.,
1998; McFadden et al., 1997; Smith et al., 1996), interferon
(IFN)-g (Upton et al., 1992), IFN-a/b (Colamonici et al., 1995;
Symons et al., 1995), and interleukin-1b (Alcamı´ and Smith,
1992; Spriggs et al., 1992). Thus, the inhibition of proinflam-
matory cytokines appears to be a widely adopted strategy
used by poxviruses to foster virus survival in the presence
of an aggressive innate host immune response.
The selective activation and recruitment of inflamma-
tory cells to sites of virus infection are mediated by a
superfamily of low-molecular-weight chemoattractant cy-
tokines known collectively as chemokines (Baggiolini,
1998; Luster, 1998). The chemokine superfamily is di-
vided into four subfamilies (CXC, CC, C, and CXXXC)
based on the structural arrangements of conserved cys-
teine residues within their peptide sequences. Members
of the CC-chemokine subfamily, such as macrophage
inflammatory protein-1a (MIP-1a), monocyte chemoat-
tractant peptide-1 (MCP-1), and regulated upon activa-
tion normal T-cell expressed and secreted (RANTES), are
generally potent activators of monocytes/macrophages,
whereas members of the CXC-chemokine subfamily,
such as interleukin-8 (IL-8) and growth-related oncogene
a (GROa), stimulate the activities of neutrophils. Apart
from inducing the directional migration of specific leuko-
cytes to sites of tissue damage and infection, chemo-
kines impart multiple biological effects in a variety of cell
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types by binding to specialized receptors that belong to
the seven-transmembrane G protein-coupled receptor
superfamily (Murphy, 1996; Premack and Schall, 1996).
Given the paramount role of chemokines in early in-
flammatory responses to pathogens, it is not surprising
that viruses have adopted specific countermeasures to
block early signals that promote leukocyte trafficking into
virus-infected tissues (Lalani and McFadden, 1997; Mur-
phy, 1997). We recently identified a new family of poxvi-
rus-encoded 35–40-kDa secreted proteins that bind
members of both the CC- and CXC-chemokine subfami-
lies in vitro as deduced by cross-linking analyses (Gra-
ham et al., 1997). The prototypic members of these sol-
uble chemokine-binding proteins include the “major se-
creted 35-kDa” protein expressed by rabbitpox virus
(RPV), a member of the Orthopoxvirus genus, and the
M-T1 gene product of myxoma virus, a specific pathogen
of rabbits belonging to the Leporipoxvirus genus.
In vitro, unfractionated M-T1 from crude myxoma virus-
infected cellular supernatants was shown to be capable
of forming cross-linked complexes with both CC-chemo-
kines (RANTES) and CXC-chemokines (IL-8), but compe-
tition binding analyses suggested that M-T1 only inter-
acts with CC-chemokines such as RANTES with high
avidity. Recently, other investigators have demonstrated
that the “major secreted 35-kDa” proteins expressed by a
variety of orthopoxviruses (vaccinia strain Lister, variola,
and cowpox viruses) bind human CC-chemokines with
subnanomolar affinities, which effectively prevents their
engagement with cell surface chemokine receptors,
thereby indirectly inhibiting intracellular calcium release
and chemotaxis (Alcamı´ et al., 1998; Smith et al., 1997a).
In vivo, we have shown that the expression of the related
35-kDa protein from RPV appears to dramatically affect
the infiltration of leukocytes into RPV-infected tissues
(Graham et al., 1997).
Sequence analysis predicts no apparent homology
between the T1/35kDa family members and any known
cellular genes, including chemokine receptors, suggest-
ing a novel mechanism for the basis of their chemokine
interaction. In fact, the leporipoxvirus T1 proteins and the
orthopoxvirus 35kDa proteins share only 40% amino acid
identity with each other. Given the divergent sources of
T1/35kDa family members in terms of host species re-
striction, it was of particular interest to determine
whether the interactions of these proteins with chemo-
kines exhibited any of the species specificities noted for
certain other poxvirus viroceptors, such as those specific
for TNF or IFN (Mossman et al., 1995; Schreiber and
McFadden, 1994). In this report, we purified M-T1 protein
from myxoma virus and the “major secreted 35-kDa”
proteins from RPV and vaccinia virus (VV) (strain Lister)
to comparatively analyze their CC-chemokine inhibitory
properties in vitro. Here we show that RPV-35kDa, VV-
35kDa, and M-T1 all potently inhibited the biological
activities of CC-chemokines with comparable efficacies
in a species-nonspecific fashion. Despite the significant
sequence divergence between the leporipoxvirus T1 and
orthopoxvirus 35kDa proteins, these data suggest that
their CC-chemokine binding and inhibitory properties are
likely to reside within the limited regions of conservation.
RESULTS
Purification of M-T1, VV-35kDa, and RPV-35kDa
glycoproteins
Sequence analysis of the leporipoxvirus T1 and or-
thopoxvirus 35kDa proteins predicts no homology to any
known cellular proteins in the database, including known
chemokine receptors; therefore, the molecular mecha-
nisms governing the interaction between chemokines
and the poxvirus proteins remains enigmatic. Given the
limited (40%) conservation of amino acid identity be-
tween the leporipoxvirus and orthopoxvirus T1/35kDa
family members, we purified M-T1 from myxoma virus
and two orthopoxvirus 35kDa family members, RPV-
35kDa and VV-35kDa, to apparent homogeneity to deter-
mine whether the functional specificities between these
proteins differ and for comparative analyses of their
inhibitory properties in vitro. Previous studies have
shown that unlike many orthopoxviruses that express
only one type of secreted chemokine binding protein
(Alcamı´ et al., 1998), myxoma virus expresses a second
distinct soluble glycoprotein, M-T7, which also demon-
strates the biochemical property of binding to a broad
spectrum of chemokines (Lalani et al., 1997). Thus, to
study M-T1 in the absence of M-T7, we fractionated M-T1
from proteins secreted from an M-T7 knockout recombi-
nant myxoma virus (vMyxlac-T7gpt) defective for M-T7
expression. VV-35kDa and RPV-35kDa were obtained
from secreted proteins from VV- (strain Lister) and RPV-
infected cells. Given the highly acidic nature of the T1/
35kDa family of proteins (Graham et al., 1997), we ex-
ploited the use of anion-exchange chromatography to
fractionate M-T1, VV-35kDa, and RPV-35kDa. As shown in
Figure 1, concentrated proteins harvested from virus-
infected cells (Figs. 1A, 1C, and 1E, lanes 1) were frac-
tionated by a dual-step procedure using a Mono Q col-
umn. A primary protein species of the predicted molec-
ular mass of 35–40 kDa (Figs. 1A, 1C, and 1E, lanes 2)
was detected in fractions eluting at a predicted high
molar salt concentration of the elution buffer. To further
purify these proteins from minor copurifying contami-
nants, pooled fractions containing the putative proteins
were subjected to a second round of anion exchange or
gel filtration chromatography, and the corresponding
fractions revealed a single prominent species of an ap-
parent molecular mass of 43 kDa for M-T1 (Fig. 1A, lane
3) and 35 kDa for VV-35kDa (Fig. 1C, lane 3) and RPV-
35kDa (Fig. 1E, lane 3) under denaturing conditions.
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To verify that the proteins purified were indeed the
products of the myxoma virus-T1, VV-C23L/B19R and
RPV-35kDa open reading frames, unfractionated (Figs.
1B, 1D, and 1F, lanes 1) and purified putative M-T1 (Fig.
1B), VV-35kDa (Fig. 1D) or RPV-35kDa (Fig. 1F) species
were subjected to immunoblotting with antiserum de-
signed specifically against respective proteins. Immuno-
blotting analyses of protein fractions collected after both
purification steps (Figs. 1B, 1D, and 1F, lanes 2 and 3)
identified a single protein species of the pre-
dicted molecular mass, confirming that the purified pro-
teins are indeed M-T1, VV-35kDa, and RPV-35kDa, re-
spectively. Moreover, microsequencing and peptide
analysis demonstrated that fractionated M-T1 was .95%
pure and confirmed the N-terminal amino acid sequence,
TKGICRQGE-, of M-T1 after the predicted signal cleavage
sequence (data not shown). Analysis of the M-T1 peptide
sequence reveals two putative N-linked glycosylation
sites and a predicted molecular mass of ;30 kDa (Gra-
ham et al., 1997). Given the discrepancy of the predicted
(30 kDa) and apparent (43 kDa) molecular masses of
M-T1 observed under SDS–PAGE conditions, we tested
whether these differences could be due to N-linked gly-
cosylation. Treatment of purified M-T1 with the enzyme
N-glycosidase F resulted in the deglycosylation of the
protein to ;37–40 kDa (Fig. 1B, lane 4), suggesting that
at least one posttranslation modification of M-T1 in-
cludes the linkage of N-linked oligosaccharides to the
viral peptide.
Purified M-T1, VV-35kDa, and RPV-35kDa bind
CC-chemokines
We previously demonstrated that M-T1, VV-35kDa,
and RPV-35kDa from unfractionated virally infected
cellular supernatants can form cross-linked com-
plexes with chemokines in vitro (Graham et al., 1997).
To verify that this interaction is independent of other
viral proteins or virally induced cellular proteins, puri-
fied M-T1, VV-35kDa, and RPV-35kDa were tested for
their ability to form protein complexes with two radio-
labeled human CC-chemokines, MIP-1a and MCP-1.
As shown in Figures 2A and 2B, column fractions
containing partially purified M-T1 or RPV-35kDa (lanes
3 and 6, respectively), or purified M-T1, RPV-35kDa, or
VV-35kDa (lanes 4, 7, and 9, respectively) all demon-
strated the capability to form a 1:1 shifted cross-linked
complex with hMIP-1a (Fig. 2A) or hMCP-1 (Fig. 2B) in
an identical manner to their unfractionated viral coun-
terparts (lanes 2, 5, and 8). However, no complexes
could be detected between the radiolabeled chemo-
kines and secreted proteins from mock-infected cells
(Figs. 2A and 2B, lanes 1). Thus, the purified M-T1,
VV-35kDa, and RPV-35kDa proteins described herein
retain the previously characterized property of inter-
acting with representative members of the CC-chemo-
kine subfamily as detected by chemical cross-linking.
FIG. 1. Purification of myxoma virus-T1, vaccinia virus-35kDa, and
rabbitpox virus-35kDa proteins. M-T1 (A and B), VV-35kDa (C and D),
and RPV-35kDa proteins (E and F) were fractionated from supernatants
of virus-infected cells and analyzed by silverstaining (A, C, and E) and
immunoblotting (B, D and F). Crude supernatants (lanes 1) or pooled
fractions containing purified M-T1 or 35kDa proteins after Mono Q or
gel-filtration chromatography (lanes 2 and 3) were subjected to SDS–
12% PAGE and visualized by silverstaining or immunoblotting using
anti-M-T1 peptide antiserum (B), anti-VV-35kDa antiserum (D), or RPV-
35kDa antiserum (F) as described under Materials and Methods. Pu-
rified M-T1 was deglycosylated by treatment with N-glycosidase F (B,
lane 4) as described in Materials and Methods. (Right) SDS molecular
weight markers.
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M-T1 and 35kDa proteins block CC-chemokines
from triggering cell surface receptors and inducing
calcium fluxes
The increase of intracellular calcium from cytosolic
stores is one of the earliest events occurring in response
to the binding of chemokines to cell surface target sev-
en-transmembrane G protein-coupled receptors. To de-
termine whether the M-T1 and 35kDa proteins can effec-
tively bind chemokines and abrogate this biological ac-
tivity, we measured the inhibition of chemokine-mediated
calcium mobilization by the viral proteins in THP-1 mono-
cytes and differentiated HL-60 cells induced by CC- and
CXC-chemokines, respectively. Increasing amounts of
RPV-35kDa (1–10 nM) progressively suppressed MIP-1a-
stimulated intracellular calcium release in THP-1 cells as
shown in the representative traces in Figure 3A. M-T1,
RPV-35kDa, and VV-35kDa all prevented calcium mobili-
zation in THP-1 monocytes stimulated by MIP-1a (Fig.
4A) or MCP-1 (Fig. 4B) in a dose-dependent manner. The
representative insets shown in Figures 4A and 4B depict
graphs as described in Materials and Methods that were
used to calculate the inhibition constant, Ki, for M-T1
inhibition against MIP-1a or MCP-1. All three viral glyco-
proteins possessed varying but comparable Ki values
and showed potent inhibitory activity toward both human
CC-chemokines (Table 1). We also tested the purified
poxvirus proteins for their ability to counter CXC-
chemokine-induced signal transduction in differentiated
HL-60 cells expressing CXC-chemokine receptors. An
increased calcium response in differentiated HL-60 cells
due to stimulation with IL-8 (Figs. 3B and 4C) or GROa
(data not shown) was unaffected by coincubation with
the M-T1 or 35kDa proteins, suggesting that the T1/
35kDa family members are specific biological inhibitors
of CC-but not CXC-chemokines, which is consistent with
previous reports for other orthopoxvirus 35kDa family
members (Alcamı´ et al., 1998; Smith et al., 1997a).
Members of the T1/35kDa family inhibit CC-
chemokine-dependent migration of monocytes
Perhaps the most extensively studied activity of che-
mokines is their ability to stimulate gradient-dependent
FIG. 2. Purified M-T1, VV-35kDa, and RPV-35kDa interact with CC-chemokines in vitro. The 125I-labeled human MIP-1a (A) or 125I-labeled human
MCP-1 (B) was incubated alone (lanes 1) or with myxoma virus-infected cellular supernatants (lanes 2), partially purified M-T1 (lanes 3), purified M-T1
(lanes 4), crude RPV-infected cellular supernatants (lanes 5), partially purified RPV-35kDa (lanes 6), purified RPV-35kDa (lanes 7), crude VV (strain
Lister) supernatants (lanes 8), or purified VV-35kDa (lanes 9) and cross-linked as described under Materials and Methods. The formation of M-T1–
or 35kDa–chemokine-shifted complexes (arrows) was detected by autoradiography after SDS–12% PAGE. (Right) SDS molecular weight markers.
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chemotaxis of various immune cells using modified Boy-
den chambers. To determine whether all members of the
T1/35kDa family comparably inhibit this biological func-
tion of chemokines, we tested the ability of M-T1, VV-
35kDa, and RPV-35kDa to block chemokine-mediated
migration of human monocytes or neutrophils. As shown
in Figure 5, unidirectional migration (chemotaxis) of hu-
man primary monocytes in response to human MIP-1a
(hMIP-1a) could be inhibited by purified M-T1 (Fig. 5A),
VV-35kDa (Fig. 5B), or RPV-35kDa (Fig. 5C) in a dose-
dependent manner. To quantify the inhibitory effects of
M-T1 and 35kDa proteins in blocking MIP-1a activity, we
determined the percentage of migration inhibition of
monocytes in response to increasing amounts of the viral
proteins (see Materials and Methods). The 50% inhibitory
concentration (IC50) of the T1/35kDa family for abrogat-
ing hMIP-1a activity was determined to be commensu-
rable (6–11 nM) among the three different viral proteins
(Table 1). M-T1, VV-35kDa, and RPV-35kDa were also
observed to effectively inhibit the activities of human
MCP-1, RANTES, and MIP-1b from stimulating human
monocyte chemotaxis in a similar fashion (data not
shown). To demonstrate that the observed inhibition is
dependent on members of the T1/35kDa family, incuba-
tion of MIP-1a with a molar equivalent amount of SERP1
(Macen et al., 1993), a distinct soluble myxoma virus
glycoprotein with no known chemokine-binding proper-
ties, did not significantly affect MIP-1a-stimulated mono-
cyte chemotaxis (Fig. 5B, bottom lane). Moreover, mono-
cyte migration in response to formyl-methionyl-leucyl-
phenylalanine (fMLP) and C5a, two distinct potent
nonchemokine chemoattractants, was not blocked by the
FIG. 3. Effect of RPV-35kDa on chemokine-induced intracellular calcium mobilization. Chemokine was briefly preincubated (5 min) with the
indicated amount of purified RPV-35kDa protein before adding it to Fura-2-loaded cells. (Arrow) Time at which the chemokine with or without
RPV-35kDa protein was added. Changes in calcium concentration were monitored by ratio fluorescence. Intracellular calcium mobilization was
measured in (A) THP-1 monocytes treated with 10 nM concentration of the human CC-chemokine, MIP-1a, or (B) differentiated HL-60 cells treated
with 10 nM concentration of the human CXC-chemokine, IL-8,in either the presence or absence of RPV-35kDa protein. The tracings shown are from
a single experiment that was representative of three separate experiments.
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M-T1 or 35kDa proteins, suggesting that the inherent
migratory capacity of the monocytes is not altered by the
viral glycoproteins and that the chemotaxis inhibition
observed is independent of fMLP and C5a receptors (Fig.
5F and data not shown). To demonstrate that the inhibi-
tory properties of the T1/35kDa family are CC-chemokine
specific, we also tested the ability of the poxvirus pro-
teins to inhibit the chemotactic activity of IL-8. Incubation
of a 0.1–10-fold molar excess amount of M-T1 (Fig. 5D) or
VV-35kDa (Fig. 5E) with IL-8 did not hinder the migration
of human primary neutrophils in response to the CXC-
chemokine, which is consistent with our observations
and previous reports that the 35-kDa viral proteins from
variola, vaccinia, and cowpox are specific inhibitors of
receptor binding for CC-chemokines but not CXC-
chemokines (Alcamı´ et al., 1998; Smith et al., 1997a).
Overall, our data show that all members of the T1/35kDa
family of proteins tested indeed display comparable ac-
tivity for potently inhibiting human CC-chemokines in
vitro in a species-nonspecific fashion.
DISCUSSION
The selective activation and transmigration of reactive
leukocytes mediated by chemokines are pivotal compo-
nents of the early host immune response required for
efficient clearance of an invading pathogen (Baggiolini,
1998; Luster, 1998). It is becoming increasingly evident
that large double-stranded DNA viruses, such as poxvi-
ruses and herpesviruses, have evolved to encode pro-
teins that modulate the activities of chemokines or their
receptors and thereby circumvent proinflammatory sig-
nals that promote leukocyte infiltration into virus-infected
tissues (Lalani and McFadden, 1997; McFadden et al.,
1998; Murphy, 1997). Such virus-encoded chemokine
modulators include mimics for both seven-transmem-
brane chemokine receptors and chemokine ligands;
however, the role of any of these genes in viral patho-
genesis remains unclear. The most recent examples of
viral chemokine regulators include soluble poxvirus che-
mokine-binding proteins such as the myxoma virus-T7
(M-T7) glycoprotein and the T1/35kDa family of secreted
proteins, which are conserved among many, but not all,
poxviruses (Alcamı´ et al., 1998; Graham et al., 1997;
Lalani et al., 1997; Smith et al., 1997a). Here, we purified
to apparent homogeneity representative members of the
T1/35kDa family from the Leporipoxvirus and Orthopox-
TABLE 1
T1/35kDa Inhibition Constants for CC-Chemokines
M-T1 RPV-35kDa VV-35kDa
Inhibition constant (Ki)
a
MIP-1a 0.456 nM 1.021 nM 1.027 nM
MCP-1 0.188 nM 0.072 nM 0.825 nM
50% Inhibitory concentration (IC50)
b
MIP-1a 10.50 nM 6.30 nM 10.53 nM
a Ki values calculated from the y-intercept of graphs plotting percent-
age inhibition of calcium flux by T1/35kDa (Fig. 4) as defined under
Materials and Methods.
b IC50 of T1/35kDa determined from the graphs of percentage inhi-
bition chemotaxis (Fig. 5) vs concentration of T1/35kDa as defined
under Materials and Methods.
FIG. 4. Inhibition of chemokine-induced calcium mobilization by the
T1/35kDa protein family. (A) Changes in the ratio fluorescence of
Fura-2-loaded THP-1 cells were monitored in response to stimulation
with 10 nM hMIP-1a in the presence of indicated concentrations of
M-T1 or 35kDa proteins. All values were normalized to the response
achieved from chemokine alone. Normalized calcium mobilization ac-
tivities are shown in the presence of M-T1 (hatched bars), RPV-35kDa
(black bars), or VV-35kDa (gray bars). (Inset) Representative graph used
to determine the inhibiton constant Ki for M-T1 inhibition of hMIP-1a as
described under Materials and Methods. (B) Calcium mobilization in
THP-1 cells treated with 10 nM hMCP-1 in the presence of the viral
proteins. (Inset) Determination of the Ki value of M-T1 against hMCP-1.
(C) Differentiated HL-60 cells were loaded with Fura-2 and exposed to
10 nM hIL-8 with purified M-T1 or 35kDa proteins. All of the data shown
are from three separate experiments.
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FIG. 5. M-T1 and 35kDa proteins block monocyte chemotaxis induced by CC-chemokines. Shown are representative chemotaxis assays performed
in triplicate of primary human monocytes in response to 25 nM human MIP-1a, primary human neutrophils in response to 10 nM human IL-8, primary
human monocytes in response to 100 nM fMLP, or spontaneous cell migration in response to migration buffer (MB) alone. Preincubation of increasing
amounts of M-T1 (A), VV-35kDa (B), or RPV-35kDa (C) with MIP-1a blocks stimulated chemotaxis of primary monocytes. MIP-1a chemotaxis was not
inhibited by incubation with a control purified poxvirus secreted glycoprotein, SERP-1 (B, bottom lane). Preincubation of M-T1 (D) or VV-35kDa (E) with
IL-8 does not block chemotaxis of primary neutrophils. VV-35kDa does not alter fMLP-mediated migration of primary monocytes (F).
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virus genera (i.e., M-T1, RPV-35kDa, and VV-35kDa) and
have shown that these poxviral proteins are comparably
potent functional inhibitors of human CC-chemokines but
not CXC-chemokines.
In vitro, crude preparations of M-T1 or 35kDa proteins
were each capable of forming 1:1 protein complexes with
members of both the CC- and CXC-chemokine subfami-
lies by chemical cross-linking, but cross-competition and
solid-phase binding analyses suggested that M-T1 inter-
acts with CC-chemokines with significantly higher affinity
(Graham et al., 1997). This specificity for CC-chemokines
has also been demonstrated by all of the other orthopox-
virus 35kDa family members tested so far (Alcamı´ et al.,
1998; Smith et al., 1997a). Using calcium mobilization
assays, we show that purified M-T1, RPV-35kDa, and
VV-35kDa bind and prevent human MIP-1a and MCP-1
from engaging CC-chemokine receptors and inducing
intracellular signaling in monocytes with comparably
high affinity (Ki 5 72 pM–1.02 nM). In addition, the pox-
virus proteins effectively neutralize the CC-chemokine
activity of stimulating monocyte chemotaxis in vitro. In
contrast, neither M-T1, RPV-35kDa, nor VV-35kDa was
able to prevent CXC-receptor activation by IL-8 or inhibit
IL-8-mediated neutrophil migration, suggesting that the
biological specificity of the T1/35kDa family is targeted
inhibition of the CC-chemokines.
At present, the mechanism defining the specificity of
CC-chemokine inhibition by the soluble poxvirus chemo-
kine-binding proteins remains to be determined. Given
that the T1/35kDa family of proteins are a unique class of
immunomodulatory proteins with no apparent homology
to any known chemokine receptors to date, they may
have adopted a novel strategy for antagonizing chemo-
kine-induced activities. Although the domains responsi-
ble for CC-chemokine interactions with the M-T1 or
35kDa proteins remain to be defined, comparative func-
tional analysis between divergent T1/35kDa family mem-
bers may yield clues to their mechanism of action. Here,
we report that despite the significant heterogeneity in
sequence identity between the leporipoxvirus T1 and
orthopoxvirus 35kDa proteins, their functional activities
remain essentially equivalent. This suggests that their
CC-chemokine binding or inhibitory properties may oc-
cur through conserved motifs or moieties within these
viral peptides. Alternatively, it is plausible that members
of the T1/35kDa family adopt a uniform conformation that
allows their functional inhibitory activities; however,
structural studies must be conducted to formally address
this hypothesis. Importantly, the T1/35kDa family mem-
bers do not exhibit the extent of species specificities
observed by viroceptors from leporipoxviruses for two
other cytokines, namely, TNF and IFN-g (Mossman et al.,
1995; Schreiber and McFadden, 1994). Thus, we predict
the inhibitory domains of CC-chemokines targeted by the
T1/35kDa family members to be more conserved than
the comparable domains of these latter cytokines. This
conservation implies that other inhibitor molecules to
this domain might exhibit a broader specificity than the
CC-chemokines exhibit for their cognate receptors.
CC-chemokines play a primary role in the inflamma-
tory response by inducing a wide range of biological
effects on mononuclear cells, T lymphocytes, B lympho-
cytes, natural killer cells, dendritic cells, eosinophils, and
basophils (Luster, 1998). Genetic evidence using ho-
mozygous MIP-1a mutant mice provides direct evidence
of the antiviral role of a CC-chemokine in the host im-
mune response (Cook et al., 1995). Early during virus
infection, monocytes/macrophages represent the pre-
dominant infiltrating leukocyte population into infected
lesions and are major effectors for viral clearance
(Nathanson, 1997). The expression of members of the
T1/35kDa family during a poxvirus infection has a pro-
nounced effect in the trafficking of reactive leukocytes
into virus-infected tissues, suggestive of an alteration in
chemokine function in vivo (Graham et al., 1997; Mar-
tinez-Pomares et al., 1995). Histological analysis of tis-
sues from a rabbitpox 35kDa deletion mutant virus 3
days after infection showed a marked increase in the
number of CD431 monocytes/macrophages and lympho-
cytes infiltrating into sites surrounding virus replication
compared with a wild-type RPV infection that displayed
only a sparse number of equivalent leukocytes (Graham
et al., 1997). Although it is likely that the expression of
M-T1 or 35kDa proteins may completely abolish all pleio-
tropic activities of the CC-chemokines during virus infec-
tion, our evidence suggests that at least one major bio-
logical function of the T1/35kDa protein family is to retard
the activation and chemotaxis of monocytes during the
early inflammatory response of the infected host. Given
the fact, however, that the RPV-35kDa knockout virus is
still fully virulent for rabbits, it is possible that the in-
creased level of infiltrating phagocytes remains poorly
activated in terms of their antiviral functions. This sup-
position is currently being tested by knockout analysis of
the M-T1 gene in myxoma virus.
MATERIALS AND METHODS
Viruses and cells
vMyxlac-T7gpt, a recombinant myxoma virus (strain Lau-
sanne) containing a disruption in both copies of the M-T7
gene, has been described elsewhere (Mossman et al.,
1996). VV (strain Lister) and RPV (strain Utrecht) were ob-
tained from the American Type Culture Collection (ATCC).
Myxoma and VV viruses were routinely propagated in a
baby green monkey kidney (BGMK) cell line, whereas
RPV was grown in a rabbit kidney cell line, RK13 (ATCC).
BGMK and RK13 cells were passaged in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% newborn calf serum (GIBCO BRL), 100 units/ml pen-
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icillin (BioWhittaker Inc. and Mediatech), 100 mg/ml strep-
tomycin (BioWhittaker Inc. and Mediatech), and 2 mM
glutamine (BioWhittaker Inc. and Mediatech). Enriched
populations of primary human monocytes and neutro-
phils were isolated from the blood of healthy donors as
described elsewhere (Wang et al., 1993). Briefly, human
peripheral blood was fractionated by Histopaque-1077
(Sigma Chemical Co.) density centrifugation, and the
resulting PBMC interface was further subjected to an
iso-osmotic Percoll (Sigma) gradient to yield a pure pop-
ulation of monocytes (.90%) as assessed by morpho-
logical criteria. Neutrophils were isolated from His-
topaque fractionated blood by 3% dextran (Sigma) sedi-
mentation followed by hypotonic lysis to eliminate red
blood cells. The human monocyte leukemic cell line
THP-1 (ATCC) was routinely cultured in RPMI 1640
(GIBCO BRL) supplemented with 10% fetal bovine serum,
100 units/ml penicillin, 100mg/ml streptomycin, 1 mM
sodium pyruvate (Mediatech), 10 mM HEPES, 0.05
mM 2-mercaptoethanol, and L-glutamine at 37°C with 5%
CO2. HL-60 cells, a human promyelocytic leukemic cell
line (ATCC), were maintained as a suspension culture in
Iscove’s modified Dulbecco’s medium (GIBCO BRL) sup-
plemented with 10% fetal bovine serum, penicillin, strep-
tomycin, sodium pyruvate, and L-glutamine. Expression
of the IL-8 chemokine receptor type B (IL-8RB) was in-
duced in undifferentiated HL-60 cells by culturing them in
the presence of 100 nM all-trans retinoic acid (Sigma) for
7 days as previously described (Zahn et al., 1997).
Chemokines and radiolabeling
Recombinant human chemokines, MCP-1, MIP-1a, IL-8,
and GROa and fMLP were purchased from commercial
vendors (R & D Systems and Sigma) or were generously
donated by Dr. Ian Clark-Lewis (University of British Co-
lumbia, Canada). HMIP-1a and human MCP-1 were ra-
diolabeled with 125I (NEN Life Science Products) using
Iodobeads (Pierce) as described elsewhere (Graham
et al., 1997).
Antibodies and immunoblotting analysis
To generate antisera specific for M-T1 (anti-H9MT1), a
decapeptide (-LRTPTLKACN) corresponding to the C-
terminal amino acid residues 267–276 of M-T1 was syn-
thesized by t-boc chemistry (Alberta Peptide Institute,
University of Alberta, Canada) and used to immunize
rabbits as described (Barry et al., 1997). The VV-35kDa
antiserum, 18691, was a generous gift of Dr. Arvind Patel
(MRC Virology Unit, Scotland) and has been described
elsewhere (Patel et al., 1990). Lyophilized gel fragments
containing fractionated denatured RPV-35kDa were used
to immunize rabbits and produce RPV-35kDa antisera.
To detect M-T1, RPV-35kDa, and VV-35kDa proteins, an
aliquot of concentrated crude supernatants from virus-
infected cells or column-fractionated viral proteins con-
taining ;250 ng of M-T1 or 35kDa were subjected to
SDS–12% PAGE and transferred to HyBond-C supported
nitrocellulose (Amersham) using a semidry transfer ap-
paratus (Tyler Corp.) for 1 h at 50 mA. Membranes were
blocked overnight in Tris-buffered saline (TBS) contain-
ing 5% skim-milk powder and 0.2% Tween 20 (ICN Bio-
medicals Inc.), probed with (1:10,000) anti-M-T1, (1:10,000)
anti-VV-35kDa, or (1:5,000) anti-RPV-35kDa antiserum for
1 h followed by a 1-h incubation with (1:5,000) horserad-
ish peroxidase-conjugated goat anti-rabbit IgG second-
ary antibody (Jackson ImmunoResearch Lab.) and visu-
alized by enhanced chemiluminescence (Amersham). To
demonstrate the specificity of the antisera against the
purified proteins, parallel blots were probed with respec-
tive preimmune sera and no cross-reacting species were
detected (data not shown).
Purification of M-T1, VV-35kDa, and RPV-35kDa
M-T1 and the 35kDa proteins were fractionated from
crude supernatants from vMyxlac-T7gpt-, VV- (strain Lister),
or RPV-infected cells using fast performance liquid chro-
matography. Briefly, VV and vMyxlac-T7gpt were ad-
sorbed onto roller bottles containing 3 3 108 BGMK cells
at an m.o.i. of 2.5 pfu/cell for 3 h. The cells were washed
with PBS three times and incubated with serum-free
DMEM at 37°C for 12–18 h, after which the medium was
harvested, centrifuged at 10,000 g for 1 h to remove virus
and cellular debris, concentrated 10-fold with a stirred
ultrafiltration cell (Amicon), and dialyzed against low-
ionic-strength buffer A (25 mM Tris buffer, pH 7.5). Then,
;5 mg of concentrated viral supernatants was loaded
onto a preequilibrated Mono Q HR5/5 (Pharmacia) anion-
exchange column and washed with 20 column volumes
of buffer A to remove unbound cationic proteins. Proteins
were eluted from the column by increasing the counte-
rion concentration from 0 to 600 mM NaCl in a dual-step
gradient at a flow rate of 0.5 ml/min on an AKTA Purifier
(Pharmacia). Aliquots of fractionated proteins were sub-
jected to SDS–12% PAGE and visualized by immunoblot-
ting or silverstaining (BioRad). VV-35kDa was routinely
detected in fractions containing 400–450 mM NaCl,
whereas M-T1 was consistently eluted at 500–550 mM
NaCl under these conditions. To further fractionate M-T1
and VV-35kDa from slight copurifying impurities, en-
riched M-T1- or VV-35kDa-containing fractions were
pooled and subjected to another round of Mono Q puri-
fication. Fractions containing purified M-T1 or VV-35kDa
were pooled, dialyzed in PBS overnight, concentrated
5-fold with a Centriprep (Amicon) concentrator, and
stored at 4°C. Then, 500 pmol of the purified myxoma
virus protein was subjected to nine cycles of automated
Edman’s degradation (Alberta Peptide Institute, Univer-
sity of Alberta, Canada), and peptide sequence analysis
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confirmed the N-terminal nine amino acid residues of
processed M-T1 (data not shown).
Conditions for obtaining and purifying the RPV-35kDa
protein were similar with a few differences. RPV was
adsorbed onto roller bottles containing 2 3 108 RK13
cells at an m.o.i. of 5 pfu/cell for 2 h, and the cells were
washed three times with PBS. Serum-free virus superna-
tants were harvested 16 h later, clarified and concen-
trated as described above, and dialyzed overnight
against 25 mM bis-Tris buffer, pH 6.0. Approximately 5
mg of concentrated proteins was loaded onto an equili-
brated Mono Q HR5/5 column, and the bound proteins
were eluted with a continuous 150–600 mM NaCl gradi-
ent at a flow rate of 1.0 ml/min. Fractions were analyzed
as stated previously. RPV-35kDa eluted from the column
at concentrations of 280–350 mM NaCl. Fractions con-
taining the Mono Q-purified RPV-35kDa were pooled
together, dialyzed against PBS overnight, concentrated
to ,250 ml, and loaded onto an equilibrated Superdex 75
gel filtration column (Pharmacia) at a rate of 0.5 ml/min to
remove any remaining minor contaminants. Fractions
containing purified RPV-35kDa were pooled and concen-
trated.
Deglycosylation of M-T1
Approximately 250 ng of M-T1 was deglycosylated
with 0.5 units of N-glycosidase F (Boehringer-Mannheim)
essentially as described elsewhere (Schreiber and Mc-
Fadden, 1996), except the final reaction products were
precipitated using a methanol–chloroform procedure
(Wessel and Flu¨gge, 1984) before immunoblotting.
Gel mobility shift cross-linking assay
The interactions of the M-T1 or 35kDa proteins with
CC-chemokines were detected using a chemical cross-
linking assay as outlined elsewhere (Graham et al., 1997;
Upton et al., 1992). Briefly, unfractionated or purified
M-T1, RPV-35kDa, or VV-35kDa was incubated with ra-
diolabeled chemokine for 2 h at room temperature, after
which time the protein complexes were cross-linked by
the addition of 1-ethyl-3-(3-dimethylaminopropyl)carbodi-
imide (Sigma) to a final concentration of 40 mM for 30
min and quenched by the addition of 1/10 volume of Tris,
pH 7.5. SDS loading buffer was added to the mixtures,
which were then boiled for 3 min and subjected to
SDS–12% PAGE, and the resulting protein complexes
were detected by autoradiography.
Calcium flux assays
Intracellular calcium mobilization in response to che-
mokine stimulation was monitored in THP-1 (for CC-
chemokines) and differentiated HL-60 cells (for CXC-
chemokines) using the fluorescent probe Fura-2 as pre-
viously described (Grynkiewicz et al., 1985). Briefly, cells
were suspended in 2 ml of serum-free medium, treated
with 5 mM Fura-2AM (Molecular Probes) for 30 min in the
dark at 37°C, washed three times with Hanks’ balanced
salt solution (GIBCO BRL) plus 1 mg/ml bovine serum
albumin (BSA) (Sigma), and finally resuspended at a
concentration of 3 3 106 cells/ml. A total of 6 3 106 cells
were transferred to a continuously stirred quartz cuvette
in a RatioMaster Fluorescence Spectrometer (Photon
Technology International). The emission of Fura-2 fluo-
rescence was monitored once every second at 510 nm
as a result of excitation at 340 nm (Fura-2 bound to Ca21)
and 380 nm (unbound Fura-2) using Felix Version 1.2
software for Windows. Ratios of the emissions from
these two excitations were automatically calculated. The
peak change in the ratio after the addition of a 10 nM
dose of human chemokine in the presence or absence of
purified viral protein was measured and quantified as a
percentage of the response obtained from subsequent
stimulation with 10 mM ATP to control for variations
between different cell preparations. Each assay was
performed in triplicate. The overall calcium mobilization
activity was calculated as (peak change in ratio due to
chemokine stimulation in the presence of viral protein)/
(peak change in ratio due to chemokine stimulation
alone). The inhibition constant Ki, defined as the concen-
tration of M-T1 or 35kDa protein necessary to block 50%
chemokine receptor engagement, was calculated as the
y-intercept from the graphs plotting the relationship of
Dt(1 2 i)/i, which is defined as the (concentration of M-T1
or 35kDa)(remaining activity)/inhibition against the frac-
tion of remaining activity.
Chemotaxis assays
Cell migration of monocytes and neutrophils was eval-
uated using a 48-well microchemotaxis chamber tech-
nique (Falk et al., 1980). Before migration assays, mono-
cytes and neutrophils were washed and resuspended in
RPMI 1640 medium containing 1 mg/ml BSA. A 30-ml
aliquot of chemoattractant (with or without indicated mo-
lar excess quantities of M-T1 or 35kDa proteins) diluted
in RPMI 1640 medium containing 1 mg/ml BSA was
placed in the lower wells, and 50 ml of cell suspension
(1.5 3 106 monocytes/ml or 1.0 3 106 neutrophils/ml) was
placed in the upper wells of a chemotaxis chamber
(Neuroprobe). The two compartments of the chamber
were separated by a 5-mm pore size polycarbonate filter
(Neuroprobe). After incubation for 90 min (for monocytes)
or 60 min (for neutrophils) at 37°C, the filter was removed
and fixed and stained with LeukoStat (Fisher Scientific),
and the number of migrating cells in 3 high-power fields
was enumerated. Chemotaxis assays were performed in
a minimum of three independent experiments, and the
results are expressed as the mean value (6 SD) of
cellular migration of triplicate samples. The percent in-
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hibition of migration was calculated as follows: [1 2
(chemokine-stimulated migration in presence of viral
protein 2 spontaneous migration/chemokine-stimulated
migration in absence of viral protein 2 spontaneous
migration)] 3 100. The IC50 of the M-T1 or 35kDa proteins
required to block CC-chemokine biological activity was
determined from the plots of percentage of migration
inhibition versus concentration of input viral proteins
(data not shown).
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